484 related articles for article (PubMed ID: 12720132)
1. Malignant transformation in IgM monoclonal gammopathy of undetermined significance.
Montoto S; Rozman M; Rosiñol L; Nadal E; Giné E; Aymerich M; Ferrer A; Esteve J; Bosch F; López-Guillermo A; Bladé J; Montserrat E
Semin Oncol; 2003 Apr; 30(2):178-81. PubMed ID: 12720132
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.
Kyle RA; Therneau TM; Rajkumar SV; Offord JR; Larson DR; Plevak MF; Melton LJ
Semin Oncol; 2003 Apr; 30(2):169-71. PubMed ID: 12720130
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system.
Baldini L; Goldaniga M; Guffanti A; Broglia C; Cortelazzo S; Rossi A; Morra E; Colombi M; Callea V; Pogliani E; Ilariucci F; Luminari S; Morel P; Merlini G; Gobbi P
J Clin Oncol; 2005 Jul; 23(21):4662-8. PubMed ID: 16034042
[TBL] [Abstract][Full Text] [Related]
4. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance.
Gregersen H; Mellemkjaer L; Ibsen JS; Dahlerup JF; Thomassen L; Sørensen HT
Haematologica; 2001 Nov; 86(11):1172-9. PubMed ID: 11694403
[TBL] [Abstract][Full Text] [Related]
5. Predictive variables for malignant transformation in 452 patients with asymptomatic IgM monoclonal gammopathy.
Morra E; Cesana C; Klersy C; Varettoni M; Cavanna L; Canesi B; Tresoldi E; Barbarano L; Lazzarino M;
Semin Oncol; 2003 Apr; 30(2):172-7. PubMed ID: 12720131
[TBL] [Abstract][Full Text] [Related]
6. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?
Gobbi PG; Baldini L; Broglia C; Goldaniga M; Comelli M; Morel P; Morra E; Cortelazzo S; Bettini R; Merlini G
Clin Cancer Res; 2005 Mar; 11(5):1786-90. PubMed ID: 15756000
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal gammopathies of undetermined significance.
Kyle RA; Rajkumar SV
Best Pract Res Clin Haematol; 2005; 18(4):689-707. PubMed ID: 16026745
[TBL] [Abstract][Full Text] [Related]
8. A long-term study of prognosis in monoclonal gammopathy of undetermined significance.
Kyle RA; Therneau TM; Rajkumar SV; Offord JR; Larson DR; Plevak MF; Melton LJ
N Engl J Med; 2002 Feb; 346(8):564-9. PubMed ID: 11856795
[TBL] [Abstract][Full Text] [Related]
9. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy.
Baldini L; Guffanti A; Cesana BM; Colombi M; Chiorboli O; Damilano I; Maiolo AT
Blood; 1996 Feb; 87(3):912-8. PubMed ID: 8562962
[TBL] [Abstract][Full Text] [Related]
10. Immunoglobulin heavy chain sequence analysis in Waldenstrom's macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance.
Rollett RA; Wilkinson EJ; Gonzalez D; Fenton JA; Short MA; Evans PA; Rawstron AC; Owen RG
Clin Lymphoma Myeloma; 2006 Jul; 7(1):70-2. PubMed ID: 16879773
[TBL] [Abstract][Full Text] [Related]
11. Waldenström macroglobulinaemia and IgM monoclonal gammopathy of undetermined significance: emerging understanding of a potential precursor condition.
McMaster ML; Caporaso N
Br J Haematol; 2007 Dec; 139(5):663-71. PubMed ID: 18021080
[TBL] [Abstract][Full Text] [Related]
12. 6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance.
Schop RF; Van Wier SA; Xu R; Ghobrial I; Ahmann GJ; Greipp PR; Kyle RA; Dispenzieri A; Lacy MQ; Rajkumar SV; Gertz MA; Fonseca R
Cancer Genet Cytogenet; 2006 Sep; 169(2):150-3. PubMed ID: 16938573
[TBL] [Abstract][Full Text] [Related]
13. IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenström's macroglobulinemia (SWM).
Kyle RA; Dispenzieri A; Kumar S; Larson D; Therneau T; Rajkumar SV
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):74-6. PubMed ID: 21454195
[TBL] [Abstract][Full Text] [Related]
14. Fracture risk in patients with monoclonal gammopathy of undetermined significance.
Gregersen H; Jensen P; Gislum M; Jørgensen B; Sørensen HT; Nørgaard M
Br J Haematol; 2006 Oct; 135(1):62-7. PubMed ID: 16925792
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic criteria of multiple myeloma.
Kyle RA
Hematol Oncol Clin North Am; 1992 Apr; 6(2):347-58. PubMed ID: 1582977
[TBL] [Abstract][Full Text] [Related]
16. Asymptomatic Waldenstrom's macroglobulinemia.
Alexanian R; Weber D; Delasalle K; Cabanillas F; Dimopoulos M
Semin Oncol; 2003 Apr; 30(2):206-10. PubMed ID: 12720137
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Owen RG; Treon SP; Al-Katib A; Fonseca R; Greipp PR; McMaster ML; Morra E; Pangalis GA; San Miguel JF; Branagan AR; Dimopoulos MA
Semin Oncol; 2003 Apr; 30(2):110-5. PubMed ID: 12720118
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells.
Sezer O; Heider U; Zavrski I; Possinger K
Haematologica; 2001 Aug; 86(8):837-43. PubMed ID: 11522540
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance.
Kumar S; Rajkumar SV; Kyle RA; Lacy MQ; Dispenzieri A; Fonseca R; Lust JA; Gertz MA; Greipp PR; Witzig TE
J Clin Oncol; 2005 Aug; 23(24):5668-74. PubMed ID: 16110026
[TBL] [Abstract][Full Text] [Related]
20. Factors predicting transformation of asymptomatic IgM monoclonal gammopathy.
Greco A; Tedeschi A; Varettoni M; Nichelatti M; Paris L; Ricci F; Vismara E; Morra E
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):77-9. PubMed ID: 21454196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
